首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1963865

解剖病理學溯源解決方案市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、最終用戶、地區和競爭格局分類，2021-2031年

Anatomic Pathology Track & Trace Solution Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By End User, By Region & Competition, 2021-2031F

出版日期: 2026年01月19日 | 出版商:

TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球解剖病理追蹤解決方案市場預計將從 2025 年的 6.7393 億美元成長到 2031 年的 10.3892 億美元，複合年成長率為 7.48%。

這些解決方案包含整合的軟硬體架構，旨在監控整個實驗室工作流程中的生物檢體，確保準確識別並維持嚴格的儲存控制。市場成長的主要驅動力是全球慢性疾病發病率的上升（這些疾病需要進行組織診斷）以及消除威脅患者安全的分析前誤差的迫切需求。此外，檢查室認證的嚴格監管要求也迫使各機構採用這些自動化識別技術，以降低責任風險並提高營運效率。

市場概覽
預測期	2027-2031
市場規模：2025年	6.7393億美元
市場規模：2031年	1,038,920,000 美元
複合年成長率：2026-2031年	7.48%
成長最快的細分市場	醫院檢查室
最大的市場	北美洲

儘管存在這些市場促進因素，但該市場仍面臨許多障礙，例如實施所需的大量資金以及與現有診斷資訊基礎設施整合的難度。診斷資源日益緊張，預算縮減，而效率提升卻迫在眉睫，這些障礙因此而加劇。根據美國癌症協會預測，2024年美國將新增約2,001,140例癌症病例。診斷需求的激增凸顯了建立強大追蹤能力的迫切性，而經濟挑戰也使這一目標的實施變得更加複雜。

市場促進因素

全球癌症和慢性疾病負擔的日益加重是組織病理學領域採用可追溯性解決方案的主要驅動力，也因此對組織診斷的處理能力和準確性提出了更高的要求。隨著腫瘤疾病發生率的上升，檢查室面臨巨大的壓力，需要在保證準確性的前提下快速處理日益增多的切片檢查檢體。診斷需求的激增使得自動化可追溯性系統成為管理複雜工作流程並確保從檢體採集到儲存整個流程完整性的必要手段。美國癌症協會2025年1月發布的《2025年癌症事實與數據》報告強調了這種可擴展基礎設施的必要性，該報告預測，僅在美國就將新增2,041,910例癌症病例。

同時，減少誤診和誤認的重要性日益凸顯，這促使檢查室實施穩健的控制鏈技術，以確保病患安全。由於人工貼標和處理日益被視為高風險且不永續，因此，利用條碼和RFID技術的追蹤系統正逐漸被採用，以避免責任風險並滿足嚴格的品質標準。行業監管機構也強調了對安全的重視。在2025年3月發布的《ECRI 2025年十大病人安全問題》報告中，與癌症和重大血管事件相關的誤診被列為第七大挑戰。此外，監管合規性也在推動這一趨勢，美國病理學家協會（CAP）2025年3月的報告也印證了這一點。報告指出，2024年共有創紀錄的657家檢查室獲得初步認證，顯示各實驗室對標準化和零錯誤操作的承諾正在不斷加深。

市場挑戰

在解剖病理學領域實施可追溯性解決方案需要大量的資金投入，這成為市場成長的主要障礙。檢查室需要承擔高昂的硬體和軟體初始成本，而將這些現代化工具連接到現有實驗室資訊系統所需的額外費用更加劇了這項挑戰。對於預算有限、缺乏資源承擔複雜整合網路基礎設施升級和員工再培訓相關成本的小規模獨立機構而言，這種財務負擔尤其沉重。

這些經濟困境因外部財政限制而進一步加劇，這些限制減少了可用於技術進步的資金。當檢查室面臨收入下降時，它們往往被迫優先考慮眼前的營運成本，而非資本投資。據美國病理學家學會稱，2024年聯邦醫療保險（Medicare）醫生報銷方案的最終草案將病理實驗室服務的整體支付額削減了約2%。報銷額的減少直接阻礙了病理實驗室集團獲得自動化追蹤系統預算的能力，儘管這些系統具有明顯的營運優勢，但卻導致其應用被推遲。

市場趨勢

追蹤系統與數位病理工作流程的整合正迅速成為一種變革性趨勢，推動市場從實體追蹤轉向全面的診斷資料管理。這種融合滿足了將實體檢體與數位對應物（例如全玻片影像 (WSI)）關聯起來的日益成長的需求，確保即使在虛擬診斷領域也能維護儲存鏈。隨著遠距離診斷和遠端病理的普及，同步玻片和數位副本之間的識別資訊對於業務連續性至關重要。根據 Labcorp 於 2024 年 2 月發布的《2024 年實驗室領導者報告》，約 33% 的實驗室決策者已經開始實施或規劃數位病理工作流程，而對能夠彌合物理和數位落差的追蹤解決方案的需求也在不斷成長。

同時，與實驗室資訊系統 (LIS) 和電子健康記錄 (EHR) 的無縫互通性已成為一項關鍵的市場需求，這要求的是深度雙向資料整合，而非簡單的連接。檢查室正在摒棄那些造成數據孤島的獨立追蹤解決方案，轉而採用能夠自動填充整個企業 IT 環境中的存取數據並即時更新病例狀態的系統。這一趨勢的驅動力在於消除冗餘資料輸入的需求，以及臨床醫生能夠即時獲取檢體位置資訊的需求。醫學實驗室觀察家 (Medical Laboratory Observer) 於 2024 年 4 月進行的「2024 年產業趨勢調查」凸顯了這項挑戰的迫切性。調查發現，51% 的實驗室專業人員認為互通性和資料整合的挑戰是重大障礙，這影響了市場對開放式架構追蹤平台的偏好。

The Global Anatomic Pathology Track & Trace Solution Market is projected to expand from USD 673.93 Million in 2025 to USD 1038.92 Million by 2031, registering a CAGR of 7.48%. These solutions comprise integrated hardware and software architectures designed to monitor biological specimens throughout the entire laboratory workflow, guaranteeing precise identification and maintaining a strict chain of custody. The market's growth is primarily driven by the rising global incidence of chronic diseases that demand tissue diagnostics and the imperative need to eliminate pre-analytical errors that endanger patient safety. Additionally, rigorous regulatory requirements for laboratory accreditation are compelling facilities to adopt these automated identification technologies to lower liability risks and enhance operational efficiency.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 673.93 MIllion
Market Size 2031	USD 1038.92 MIllion
CAGR 2026-2031	7.48%
Fastest Growing Segment	Hospital Laboratories
Largest Market	North America

Despite these positive drivers, the market faces obstacles due to the substantial capital required for implementation and the difficulties involved in integrating these systems with existing laboratory information infrastructures. This barrier is further exacerbated by the increasing strain on diagnostic resources, which demands higher efficiency while simultaneously tightening financial budgets. According to the American Cancer Society, approximately 2,001,140 new cancer cases were projected to occur in the United States in 2024. This escalating volume of diagnostic demand highlights the urgent necessity for robust tracking capabilities, even as economic challenges complicate their acquisition.

Market Driver

The rising global burden of cancer and chronic diseases serves as a major catalyst for the implementation of anatomic pathology track and trace solutions, creating a fundamental need for greater throughput and precision in tissue diagnostics. As oncological conditions become more prevalent, laboratories are under immense pressure to process growing volumes of biopsy specimens rapidly without sacrificing accuracy. This surge in diagnostic demand necessitates automated tracking systems to oversee complex workflows and guarantee specimen integrity from the point of collection to archiving. Highlighting this need for scalable infrastructure, the American Cancer Society's 'Cancer Facts & Figures 2025' report, released in January 2025, estimates that 2,041,910 new cancer cases will be diagnosed in the United States alone.

Simultaneously, the imperative to reduce diagnostic errors and misidentification acts as a powerful driver, pushing laboratories to adopt robust chain-of-custody technologies to ensure patient safety. Because manual labeling and handling are increasingly seen as risky and untenable, there is a distinct shift toward barcode and RFID-enabled tracking to mitigate liability and meet strict quality standards. This emphasis on safety is underscored by industry monitors; in March 2025, ECRI's 'Top 10 Patient Safety Concerns 2025' report listed diagnostic errors related to cancers and major vascular events as the seventh most critical challenge. Furthermore, regulatory compliance strengthens this trend, illustrated by the College of American Pathologists' March 2025 report, which noted that a record 657 laboratories achieved initial accreditation in 2024, signaling a deepening commitment to standardized, error-free operations.

Market Challenge

The significant capital investment needed to deploy anatomic pathology track and trace solutions represents a major hurdle to market growth. Laboratories must contend with high upfront costs for essential hardware and software, a challenge that is further complicated by the expense of interfacing these modern tools with legacy laboratory information systems. This financial strain is particularly acute for smaller, independent facilities that operate with limited budgets and lack the resources to easily absorb the costs associated with infrastructure upgrades or staff retraining for complex integrated networks.

These economic difficulties are intensified by external financial constraints that restrict the funds available for technological enhancements. When laboratories face diminished revenue streams, they are often compelled to prioritize immediate operational costs over capital equipment investments. According to the College of American Pathologists, the final Medicare Physician Fee Schedule in 2024 led to an overall payment reduction of approximately 2 percent for pathology services. This contraction in reimbursement directly hampers the ability of pathology groups to budget for automated tracking systems, delaying their adoption despite the evident operational advantages.

Market Trends

The convergence of track and trace systems with digital pathology workflows is rapidly becoming a transformative trend, evolving the market from physical tracking to comprehensive diagnostic data management. This integration addresses the increasing need to link physical specimens with their digital counterparts, such as whole slide images (WSI), ensuring the chain of custody persists into the virtual diagnostic realm. As remote sign-out and telepathology gain traction, maintaining synchronized identification between glass slides and their digital twins is essential for operational continuity. According to Labcorp's '2024 Lab Leader Report' from February 2024, approximately 33% of laboratory decision-makers have initiated or planned digital pathology workflows, driving a parallel demand for tracking solutions that bridge the physical-digital divide.

Concurrently, seamless interoperability with Laboratory Information Systems (LIS) and Electronic Health Records (EHR) has become a primary market requirement, necessitating deep, bi-directional data integration rather than simple connectivity. Laboratories are moving away from standalone tracking solutions that generate data silos, preferring systems that automatically populate accession data and update case status in real-time across the enterprise IT landscape. This trend is motivated by the need to eliminate redundant data entry and ensure specimen location data is instantly available to clinicians. The urgency of this issue is highlighted by the '2024 State of the Industry Survey' from Medical Laboratory Observer in April 2024, where 51% of laboratory professionals cited interoperability and data integration challenges as significant hurdles, thereby influencing the market's preference for open-architecture tracking platforms.

Key Market Players

Leica Biosystems Nussloch GmbH
Thermo Fisher Scientific Inc
Zebra Technologies Corp.
Agilent Technologies Inc
CompuGroup Medical
LigoLab Information Systems
General Data Healthcare Inc.
Psyche Systems Corporation
Siemens Healthineers AG
Indica Labs, LLC

Report Scope

In this report, the Global Anatomic Pathology Track & Trace Solution Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anatomic Pathology Track & Trace Solution Market, By Application

Slides Tracking
Specimen Tracking
Tissue Cassettes & Blocks Tracking

Anatomic Pathology Track & Trace Solution Market, By End User

Hospital Laboratories
Independent & Reference Laboratories
Others

Anatomic Pathology Track & Trace Solution Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anatomic Pathology Track & Trace Solution Market.

Available Customizations:

Global Anatomic Pathology Track & Trace Solution Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anatomic Pathology Track & Trace Solution Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Application (Slides Tracking, Specimen Tracking, Tissue Cassettes & Blocks Tracking)
- 5.2.2. By End User (Hospital Laboratories, Independent & Reference Laboratories, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Anatomic Pathology Track & Trace Solution Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Application
- 6.2.2. By End User
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Anatomic Pathology Track & Trace Solution Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Application
    - 6.3.1.2.2. By End User
- 6.3.2. Canada Anatomic Pathology Track & Trace Solution Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Application
    - 6.3.2.2.2. By End User
- 6.3.3. Mexico Anatomic Pathology Track & Trace Solution Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Application
    - 6.3.3.2.2. By End User

7. Europe Anatomic Pathology Track & Trace Solution Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Application
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Anatomic Pathology Track & Trace Solution Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Application
    - 7.3.1.2.2. By End User
- 7.3.2. France Anatomic Pathology Track & Trace Solution Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Application
    - 7.3.2.2.2. By End User
- 7.3.3. United Kingdom Anatomic Pathology Track & Trace Solution Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Application
    - 7.3.3.2.2. By End User
- 7.3.4. Italy Anatomic Pathology Track & Trace Solution Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Application
    - 7.3.4.2.2. By End User
- 7.3.5. Spain Anatomic Pathology Track & Trace Solution Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Application
    - 7.3.5.2.2. By End User

8. Asia Pacific Anatomic Pathology Track & Trace Solution Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Application
- 8.2.2. By End User
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Anatomic Pathology Track & Trace Solution Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Application
    - 8.3.1.2.2. By End User
- 8.3.2. India Anatomic Pathology Track & Trace Solution Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Application
    - 8.3.2.2.2. By End User
- 8.3.3. Japan Anatomic Pathology Track & Trace Solution Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Application
    - 8.3.3.2.2. By End User
- 8.3.4. South Korea Anatomic Pathology Track & Trace Solution Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Application
    - 8.3.4.2.2. By End User
- 8.3.5. Australia Anatomic Pathology Track & Trace Solution Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Application
    - 8.3.5.2.2. By End User

9. Middle East & Africa Anatomic Pathology Track & Trace Solution Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Application
- 9.2.2. By End User
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Anatomic Pathology Track & Trace Solution Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Application
    - 9.3.1.2.2. By End User
- 9.3.2. UAE Anatomic Pathology Track & Trace Solution Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Application
    - 9.3.2.2.2. By End User
- 9.3.3. South Africa Anatomic Pathology Track & Trace Solution Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Application
    - 9.3.3.2.2. By End User

10. South America Anatomic Pathology Track & Trace Solution Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Application
- 10.2.2. By End User
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Anatomic Pathology Track & Trace Solution Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Application
    - 10.3.1.2.2. By End User
- 10.3.2. Colombia Anatomic Pathology Track & Trace Solution Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Application
    - 10.3.2.2.2. By End User
- 10.3.3. Argentina Anatomic Pathology Track & Trace Solution Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Application
    - 10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Anatomic Pathology Track & Trace Solution Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Leica Biosystems Nussloch GmbH
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Thermo Fisher Scientific Inc
15.3. Zebra Technologies Corp.
15.4. Agilent Technologies Inc
15.5. CompuGroup Medical
15.6. LigoLab Information Systems
15.7. General Data Healthcare Inc.
15.8. Psyche Systems Corporation
15.9. Siemens Healthineers AG
15.10. Indica Labs, LLC